List view / Grid view
The US Food and Drug Administration (FDA) has granted Abbvie’s Humira® (adalimumab) Orphan Drug Designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease.
7 May 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation for venetoclax for the treatment of people who have relapsed or refractory CLL with 17p deletion...
27 April 2015 | By Victoria White
AbbVie announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study at ILC 2015...
31 March 2015 | By Victoria White
Biogen and AbbVie have announced that the EMA has validated the companies’ MAA for Zinbryta for the treatment of relapsing forms of MS in the EU...
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
6 March 2015 | By GlobalData
“AbbVie’s acquisition of Pharmacyclics (PCYC), valued at $21 billion, will help the company alleviate its dependency on Humira, which accounted for 62% of its total revenues in 2014, up from 57% in 2013..."
24 November 2014 | By Enanta Pharmaceuticals, Inc.
Enanta announces CHMP positive opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the treatment of chronic hepatitis C in Europe...
24 October 2014 | By GlobalData
The recent termination of AbbVie’s deal to acquire Shire makes this pharmaceuticals’ first major casualty of new US tax inversion legislation, and has jolted the industry out of its reverie, according to an analyst with research and consulting firm GlobalData.
26 September 2014 | By AbbVie
AbbVie announced that the U.S. Food and Drug Administration has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough...
18 September 2014 | By Biogen Idec
Biogen Idec and AbbVie announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity...
4 August 2014 | By AbbVie
AbbVie announced the European Medicines Agency and the U.S. Food and Drug Administration have granted orphan drug designation to AbbVie's investigational compound ABT-414...
26 June 2014 | By AbbVie
AbbVie announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888)...
23 June 2014 | By AbbVie
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $0.42 per share...
17 June 2014 | By AbbVie
AbbVie announced that the Marketing Authorization Applications for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C virus infection have been validated and are under accelerated assessment by the European Medicines Agency...
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
